New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
13:47 EDTSNY, REGNRegeneron price target raised to $382 from $362 at Roth Capital
Roth Capital raised its price target on Regeneron (REGN) after the company and partner Sanofi (SNY) presented the full data set from the ODYSSEY MONO study, along with data supporting the potential for once per month dosing with alirocumab. Roth noted that Sanofi is guiding to filing for approval for the drug in 2016.
News For REGN;SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 26, 2015
05:25 EDTREGNRegeneron reports approval of Eylea by Japan
Subscribe for More Information
June 25, 2015
14:03 EDTSNYSanofi initiated with a Buy at HSBC
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use